https://orcid.org/0000-0001-5997-7172
References
- Lommatzsch M, Brusselle GG, Canonica GW., et al. Disease-modifying anti-asthmatic drugs. Lancet. 2022;399(10335):1664–1668. doi:10.1016/S0140-6736(22)00331-2
- Menzies-Gow A, Szefler SJ, Busse WW. The relationship of asthma biologics to remission for asthma. J Allergy Clin Immunol Pract. 2021;9(3):1090–1098. doi:10.1016/j.jaip.2020.10.035
- 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: https://ginasthma.org. Accessed August 30, 2023.
- Carpaij OA, Burgess JK, Kerstjens HAM, Nawijn MC, van den Berge M. A review on the pathophysiology of asthma remission. Pharmacology & Therapeutics. 2019;201:8–24. doi:10.1016/j.pharmthera.2019.05.002
- Vonk JM, Postma DS, Boezen HM, et al. Childhood factors associated with asthma remission after 30 year follow up. Thorax. 2004;59(11):925–929. doi:10.1136/thx.2003.016246
- Westerhof GA, Coumou H, de Nijs SB, Weersink EJ, Bel EH. Clinical predictors of remission and persistence of adult-onset asthma. Journal of Allergy and Clinical Immunology. 2018;141(1):104–109. doi:10.1016/j.jaci.2017.03.034
- Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. Allergy. 2021;76:1041–1052. doi:10.1111/all.14575
- Pfaar O, Creticos PS, Kleine-Tebbe J, Canonica GW, Palomares O, Schülke S. One hundred ten years of allergen immunotherapy: a broad look into the future. J Allergy Clin Immunol Pract. 2021;9(5):1791–1803. doi:10.1016/j.jaip.2020.12.067
- Chan TC, Hu TH, Chu YH, Hwang JS. Assessing effects of personal behaviors and environmental exposure on asthma episodes: a diary-based approach. BMC Pulmonary Medicine. 2019;19(1):231. doi:10.1186/s12890-019-0998-0
- Pollack CE, Bozzi DG, Blackford AL, DeLuca S, Thornton RLJ, Herring B. Using the Moving toOpportunity experiment to investigate the long-term impact of neighborhoods on healthcare use by specific clinical conditions and type of service. Hous Policy Debate. 2023;33(1):269–289. doi:10.1080/10511482.2021.1951804
- Pollack CE, Roberts LC, Peng RD, et al. Association of a housing mobility program with childhood asthma symptoms and exacerbations. JAMA. 2023;329(19):1671–1681. doi:10.1001/jama.2023.6488
- Childhood Asthma Management Program Research Group. Szefler S, Weiss S, Tonascia J, et al. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063.
- Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834. doi:10.1002/14651858.CD010834.pub4
- Normansell R, Walker S, Milan SJ, Walters EH, Nair P, Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559. doi:10.1002/14651858.CD003559.pub4
- Fieten KB, Drijver-Messelink MT, Cogo A, et al. Alpine altitude climate treatment for severe and uncontrolled asthma: an EAACI position paper. Allergy. 2022;77(7):1991–2024. doi:10.1111/all.15242
- Adams K, Scott Weber K, Johnson SM. Exposome and Immunity training: how pathogen exposure order influences innate immune cell lineage commitment and function. Int. J. Mol. Sci. 2020;21(22):8462. doi:10.3390/ijms21228462
- Sozener ZC, Yücel UO, Altiner S, et al. The external exposome and allergies: from the perspective of the epithelial barrier hypothesis. Frontiers in Allergy. 2022. doi:10.3389/falgy.2022.887672
- Adisasmito WB, Almuhairi S, Behravesh CB, et al.; One Health High-Level Expert Panel (OHHLEP). One Health: a new definition for a sustainable and healthy future. PLoS Pathog. 2022;18(6):e1010537. doi:10.1371/journal.ppat.1010537
- Jutel M, Mosnaim GS, Bernstein JA, et al. The One Health approach for allergic diseases and asthma. Allergy. 2023;78:1777–1793. doi:10.1111/all.15755